(Q34413527)

English

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

object named as

Jan van Lunzen

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Bonaventura Clotet Sala

1

object named as

Bonaventura Clotet

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Andrea Antinori

5

object named as

Andrea Antinori

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

10

object named as

Michael Saag

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Judith Feinberg

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Marie-Aude Khuong-Josses

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Irina Dumitru

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Vadim Pokrovskiy

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jan Fehr

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Roberto Ortiz

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Julia Harris

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Clare Brennan

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Tamio Fujiwara

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sherene Min

14

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ING114915 Study Team

15

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

1 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

383

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

9936

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2222-2231

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Quad's in it for antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the HIV treatment satisfaction questionnaire (HIVTSQ).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of a self-completed HIV symptom index.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Designing and interpreting HIV noninferiority trials in naive and experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The fallback procedure for evaluating a single family of hypotheses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

General multistage gatekeeping procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of trimethoprim on serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960084-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)60084-2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34413527&oldid=1615442357"